Chonghui Zhang

USPTO Granted Patents = 11 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Brookline, MA (US) (1999 - 2020)
Cambridge, MA (US) (2023 - 2024)

Company Filing History:

Dana-farber-cancer Institute Inc.

patents

Years Active: 1999-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),

2. 11952428 - BCMA chimeric antigen receptors and uses thereof (2024-04-09),

3. 11939389 - BCMA chimeric antigen receptors and uses thereof (2024-03-26),

4. 11608382 - BCMA chimeric antigen receptors and uses thereof (2023-03-21),

5. 10870698 - Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies (2020-12-22),

6. RE47123 - EPHA2 receptor antagonist antibodies (2018-11-12),

7. 9982046 - Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies (2018-05-29),

8. 9512222 - Lectin-like oxidized LDL receptor 1 antibodies and methods of use (2016-12-06),

9. 8992912 - Methods of use for antibodies that specifically bind to the EphA2 receptor (2015-03-31),

10. 8460667 - EPHA2 receptor antagonist antibodies (2013-06-11),

11. 5935801 - Monoclonal antibody that detects apoptotic antigen (1999-08-10),

Title: The Innovative Contributions of Chonghui Zhang

Introduction

Chonghui Zhang is a prominent inventor based in Brookline, MA, known for his significant contributions to the field of immunotherapy. With a total of 11 patents to his name, Zhang has made remarkable advancements in the development of chimeric antigen receptors (CARs) that have the potential to revolutionize cancer treatment.

Latest Patents

Among his latest patents, Zhang has developed innovative immune effector cells that express chimeric antigen receptors. One notable invention focuses on immune effector cells, such as T cells and NK cells, that utilize CAR technology. This invention provides compositions and methods for enhancing the efficacy of these immune cells in targeting cancer. Another significant patent involves BCMA chimeric antigen receptors, which offer new methods for treating diseases associated with the expression of BCMA. This invention includes vectors encoding the BCMA CAR and methods for administering genetically modified T cells that express this receptor.

Career Highlights

Throughout his career, Chonghui Zhang has worked with leading pharmaceutical companies, including Novartis and Sanofi. His work in these organizations has allowed him to collaborate with some of the brightest minds in the industry, furthering the development of innovative therapies.

Collaborations

Zhang has collaborated with notable colleagues such as Jennifer Brogdon and Aida Abujoub. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Chonghui Zhang's contributions to the field of immunotherapy through his innovative patents and collaborations highlight his role as a leading inventor in the industry. His work continues to pave the way for new treatments that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.